INS and metabolic syndrome: Pemafibrate exhibits promise in modulating lipid profiles by reducing triglycerides, elevating high-density lipoprotein cholesterol levels, mitigating inflammation, and enhancing insulin sensitivity—making it a promising novel treatment for MetS (Fruchart et al., 2021).